Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib

Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib

Background: Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib. Methods: We performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who...

Full description

Bibliographic Details
Main Authors: Chute, D.F (Author), Colvin, R.B (Author), Efe, O. (Author), Fadden, R.M (Author), Jhaveri, K.D (Author), Kaufman, H.L (Author), Lee, M.D (Author), Reynolds, K.L (Author), Rosales, I.A (Author), Rusibamayila, N. (Author), Seethapathy, H. (Author), Sise, M.E (Author), Strohbehn, I.A (Author), Sullivan, R.J (Author)
Format: Article
Language:English
Published: Oxford University Press 2022
Subjects:
acute kidney failure
Acute kidney injury
Acute Kidney Injury
adult
adverse outcome
aged
antineoplastic agent
Antineoplastic Combined Chemotherapy Protocols
Article
B Raf kinase
BRAF
chill
clinical effectiveness
clinical feature
cohort analysis
corticosteroid
creatinine
creatinine blood level
dabrafenib
dipyrone
disease severity
dose response
drug effect
drug efficacy
drug safety
female
fever
follow up
gastrointestinal symptom
genetics
human
Humans
imidazole derivative
Imidazoles
interstitial nephritis
liver enzyme
major clinical study
male
MEK
melanoma
Melanoma
mutation
Mutation
Nephrotoxicity
oxime
Oximes
prescription
Proto-Oncogene Proteins B-raf
Pyridones
pyrimidinone derivative
Pyrimidinones
Retrospective Studies
retrospective study
risk factor
trametinib
treatment outcome
trend study
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items